{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"41.0","upperLimit":"55.0","value":"48.2"},{"groupId":"OG001","lowerLimit":"14.6","upperLimit":"26.1","value":"20.0"}]}],"title":"At 6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"36.3","upperLimit":"50.2","value":"43.3"},{"groupId":"OG001","lowerLimit":"3.9","upperLimit":"12.4","value":"7.4"}]}],"title":"At 12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.5","upperLimit":"47.4","value":"40.5"},{"groupId":"OG001","lowerLimit":"2.2","upperLimit":"10.2","value":"5.2"}]}],"title":"At 18 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.0","upperLimit":"42.6","value":"35.8"},{"groupId":"OG001","lowerLimit":"2.2","upperLimit":"10.2","value":"5.2"}]}],"title":"At 24 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.1","upperLimit":"39.6","value":"32.8"},{"groupId":"OG001","lowerLimit":"1.3","upperLimit":"8.9","value":"3.9"}]}],"title":"At 36 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.2","upperLimit":"36.5","value":"29.7"},{"groupId":"OG001","lowerLimit":"1.3","upperLimit":"8.9","value":"3.9"}]}],"title":"At 48 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.0","upperLimit":"35.2","value":"28.4"},{"groupId":"OG001","lowerLimit":"1.3","upperLimit":"8.9","value":"3.9"}]}],"title":"At 60 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.4","upperLimit":"34.5","value":"27.8"},{"groupId":"OG001","lowerLimit":"1.3","upperLimit":"8.9","value":"3.9"}]}],"title":"At 72 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.5","upperLimit":"32.7","value":"25.9"},{"groupId":"OG001","lowerLimit":"1.3","upperLimit":"8.9","value":"3.9"}]}],"title":"At 84 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"210"},{"groupId":"OG001","value":"208"}],"units":"Participants"}],"description":"The PFS rate at a time point is the estimated percentage of patients who have not progressed and are alive at that time point following randomization and is estimated using the Kaplan-Meier methodology.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received nivolumab, 3 mg/kg, solution administered Intravenously (IV) every 2 weeks with placebo-matching dacarbazine solution administered IV every 3 weeks, until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion","id":"OG000","title":"Nivolumab, 3 mg/kg + Placebo-matching Dacarbazine"},{"description":"Participants received dacarbazine 1000 mg/m\\^2, solution administered IV every 3 weeks with placebo-matching nivolumab solution administered IV every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion","id":"OG001","title":"Dacarbazine, 1000 mg/m^2 + Placebo-matching Nivolumab"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization to the specified timepoints, up to 84 months","title":"Progression-free Survival (PFS) Rate","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}